GlassScriptPhysician profile
Amanda J Fraser
NPI 1518135748
$8,491.58
in general payments reported to CMS, 2019-2025
31 companies · $1,792 in 2025
The $1,792 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,108 · 2022: $1,718 · 2023: $1,772 · 2024: $2,102 · 2025: $1,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,338 · Education: $185 · Honoraria: $125 · Consulting Fee: $17.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,338.22 |
| Education | $184.52 |
| Honoraria | $125.00 |
| Consulting Fee | $17.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,961.10 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,406.30 | 2022-2025 | Dupixent |
| Genzyme Corporation | $890.75 | 2021-2025 | |
| Amgen INC. | $540.21 | 2021-2025 | Tezspire |
| Pfizer INC. | $516.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $372.06 | 2021-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $342.98 | 2021-2025 | Hizentra, Andembry |
| Aimmune Therapeutics, INC. | $327.73 | 2021-2024 | |
| Abbvie INC. | $297.68 | 2021-2025 | |
| Grifols USA, LLC | $259.75 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $201.23 | 2021-2025 | Cuvitru, Hyqvia, Takhzyro |
| Incyte Corporation | $196.97 | 2021-2023 | Opzelura |
| Genentech USA, INC. | $180.24 | 2021-2023 | Xolair |
| Covis Pharma Gmbh | $131.69 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $112.55 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $107.87 | 2022-2025 | Orladeyo |
| Kaleo, INC. | $80.85 | 2021-2023 | Auvi-Q |
| Leo Pharma INC. | $80.63 | 2022-2024 | Adbry |
| Octapharma USA, INC. | $67.46 | 2023 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $58.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.91 | 2021-2022 | |
| Organon LLC | $48.82 | 2025 | |
| Alk-Abello, INC | $42.28 | 2021-2023 | Odactra, Grastek, Ragwitek |
| Mylan Specialty L.P. | $41.44 | 2024 | Yupelri |
| Hikma Pharmaceuticals USA | $35.10 | 2023-2024 | Ryaltris |
| Insmed, INC. | $28.89 | 2025 | Brinsupri |
| Blueprint Medicines Corporation | $22.96 | 2023 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $22.71 | 2025 | Dawnzera |
| Viatris Specialty LLC | $22.08 | 2025 | Yupelri |
| Galderma Laboratories, L.P. | $21.16 | 2025 | Nemluvio |
| Adma Biomanufacturing LLC | $17.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.